TW428026B - Bifunctional protein, preparation and use - Google Patents
Bifunctional protein, preparation and useInfo
- Publication number
- TW428026B TW428026B TW084103999A TW84103999A TW428026B TW 428026 B TW428026 B TW 428026B TW 084103999 A TW084103999 A TW 084103999A TW 84103999 A TW84103999 A TW 84103999A TW 428026 B TW428026 B TW 428026B
- Authority
- TW
- Taiwan
- Prior art keywords
- protein
- host cell
- preparation
- bifunctional protein
- relates
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 230000001588 bifunctional effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 4
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94810244 | 1994-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW428026B true TW428026B (en) | 2001-04-01 |
Family
ID=8218248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW084103999A TW428026B (en) | 1994-05-02 | 1995-04-24 | Bifunctional protein, preparation and use |
Country Status (18)
Country | Link |
---|---|
US (1) | US6984382B1 (zh) |
EP (1) | EP0758394B1 (zh) |
JP (1) | JP3742103B2 (zh) |
KR (1) | KR100373813B1 (zh) |
AT (1) | ATE228166T1 (zh) |
AU (1) | AU694222B2 (zh) |
CA (1) | CA2188422C (zh) |
DE (1) | DE69528894T2 (zh) |
DK (1) | DK0758394T3 (zh) |
ES (1) | ES2185705T3 (zh) |
FI (1) | FI119191B (zh) |
IL (1) | IL113530A0 (zh) |
NO (1) | NO316923B1 (zh) |
NZ (1) | NZ285395A (zh) |
PT (1) | PT758394E (zh) |
TW (1) | TW428026B (zh) |
WO (1) | WO1995030014A1 (zh) |
ZA (1) | ZA953440B (zh) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69528894T2 (de) | 1994-05-02 | 2003-03-27 | Bernd Groner | Bifunktionelles protein, herstellung und verwendung |
WO1997024446A2 (en) * | 1995-12-29 | 1997-07-10 | Chiron Corporation | Gene delivery vehicle-targeting ligands |
WO1998012227A1 (en) * | 1996-09-19 | 1998-03-26 | Diagnocure Inc. | Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
DE10121113A1 (de) * | 2001-04-28 | 2002-10-31 | Gabriele Pecher | Genmodifizierte YT Zelllinie und ihre Verwendung |
CA3052445C (en) | 2004-07-10 | 2023-08-22 | Kerry S. Campbell | Genetically modified human natural killer cell lines |
WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
EP1912675B1 (en) | 2005-07-25 | 2014-02-12 | Emergent Product Development Seattle, LLC | B-cell reduction using cd37-specific and cd20-specific binding molecules |
US8409577B2 (en) * | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
WO2008045437A2 (en) * | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
JP6013733B2 (ja) | 2008-04-11 | 2016-10-25 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Cd37免疫治療薬および二機能性化学療法薬とのその組合せ |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
SG190997A1 (en) | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
US9790278B2 (en) | 2012-05-07 | 2017-10-17 | The Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
PL2958943T3 (pl) | 2013-02-20 | 2020-04-30 | The Trustees Of The University Of Pennsylvania | Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
DK3129470T3 (da) | 2014-04-07 | 2021-07-05 | Novartis Ag | Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor |
SG11201700418VA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置 |
BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
PL3194443T3 (pl) | 2014-09-17 | 2022-01-31 | Novartis Ag | Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej |
KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
CA3197849A1 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
HUE059218T2 (hu) | 2015-04-08 | 2022-11-28 | Novartis Ag | CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel |
CA2982996A1 (en) | 2015-04-17 | 2016-10-20 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
EP3344996A2 (en) | 2015-09-03 | 2018-07-11 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
KR20180053322A (ko) | 2015-09-21 | 2018-05-21 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
EA201891338A1 (ru) | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
EP3601561A2 (en) | 2017-03-22 | 2020-02-05 | Novartis AG | Compositions and methods for immunooncology |
AR123115A1 (es) | 2017-10-18 | 2022-11-02 | Novartis Ag | Composiciones y métodos para la degradación selectiva de proteínas |
CN112055595A (zh) | 2018-01-22 | 2020-12-08 | 恩多塞特公司 | Car t细胞的使用方法 |
EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
CN110627895B (zh) * | 2018-06-25 | 2021-03-23 | 北京大学 | 肺癌特异性tcr及其分析技术和应用 |
WO2020043899A1 (en) | 2018-08-31 | 2020-03-05 | Invectys | Chimeric antigen receptors against multiple hla-g isoforms |
EP3956666A1 (en) * | 2019-04-18 | 2022-02-23 | GlaxoSmithKline Biologicals S.A. | Antigen binding proteins and assays |
MX2022006365A (es) | 2019-11-26 | 2022-06-22 | Novartis Ag | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260880A3 (en) | 1986-09-11 | 1990-03-07 | Dana-Farber Cancer Institute, Inc. | Turning on of cytotoxicity |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
FI105320B (fi) | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
AU656544B2 (en) | 1990-10-31 | 1995-02-09 | Brigham And Women's Hospital | Genetic modification of endothelial cells |
CA2074825C (en) * | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chimeric chains for receptor-associated signal transduction pathways |
AU662311B2 (en) * | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
FR2672901B1 (fr) | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
AU1453792A (en) | 1991-02-27 | 1992-10-06 | Regents Of The University Of California, The | Targeting complex mediated immunogenicity |
NZ241855A (en) | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
WO1993019163A1 (en) * | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
WO1993020840A1 (en) | 1992-04-14 | 1993-10-28 | British Bio-Technology Limited | Induction of ctl responses |
DE69528894T2 (de) | 1994-05-02 | 2003-03-27 | Bernd Groner | Bifunktionelles protein, herstellung und verwendung |
-
1995
- 1995-04-20 DE DE69528894T patent/DE69528894T2/de not_active Expired - Lifetime
- 1995-04-20 CA CA2188422A patent/CA2188422C/en not_active Expired - Lifetime
- 1995-04-20 AU AU24469/95A patent/AU694222B2/en not_active Ceased
- 1995-04-20 DK DK95918576T patent/DK0758394T3/da active
- 1995-04-20 AT AT95918576T patent/ATE228166T1/de active
- 1995-04-20 NZ NZ285395A patent/NZ285395A/xx not_active IP Right Cessation
- 1995-04-20 KR KR1019960706165A patent/KR100373813B1/ko not_active IP Right Cessation
- 1995-04-20 JP JP52796595A patent/JP3742103B2/ja not_active Expired - Fee Related
- 1995-04-20 EP EP95918576A patent/EP0758394B1/en not_active Expired - Lifetime
- 1995-04-20 WO PCT/EP1995/001494 patent/WO1995030014A1/en active IP Right Grant
- 1995-04-20 ES ES95918576T patent/ES2185705T3/es not_active Expired - Lifetime
- 1995-04-20 PT PT95918576T patent/PT758394E/pt unknown
- 1995-04-24 TW TW084103999A patent/TW428026B/zh active
- 1995-04-28 IL IL11353095A patent/IL113530A0/xx not_active IP Right Cessation
- 1995-04-28 ZA ZA953440A patent/ZA953440B/xx unknown
-
1996
- 1996-10-25 FI FI964311A patent/FI119191B/fi not_active IP Right Cessation
- 1996-11-01 NO NO19964641A patent/NO316923B1/no not_active IP Right Cessation
-
2000
- 2000-06-19 US US09/596,774 patent/US6984382B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FI964311A0 (fi) | 1996-10-25 |
FI964311A (fi) | 1996-10-25 |
DK0758394T3 (da) | 2003-03-03 |
FI119191B (fi) | 2008-08-29 |
ES2185705T3 (es) | 2003-05-01 |
NO964641L (no) | 1996-11-01 |
NO964641D0 (no) | 1996-11-01 |
EP0758394B1 (en) | 2002-11-20 |
ZA953440B (en) | 1995-11-02 |
PT758394E (pt) | 2003-04-30 |
IL113530A0 (en) | 1995-07-31 |
JPH09512176A (ja) | 1997-12-09 |
JP3742103B2 (ja) | 2006-02-01 |
US6984382B1 (en) | 2006-01-10 |
CA2188422A1 (en) | 1995-11-09 |
CA2188422C (en) | 2011-03-15 |
DE69528894T2 (de) | 2003-03-27 |
WO1995030014A1 (en) | 1995-11-09 |
NZ285395A (en) | 1998-10-28 |
NO316923B1 (no) | 2004-06-28 |
DE69528894D1 (de) | 2003-01-02 |
AU2446995A (en) | 1995-11-29 |
EP0758394A1 (en) | 1997-02-19 |
KR100373813B1 (ko) | 2003-10-08 |
AU694222B2 (en) | 1998-07-16 |
ATE228166T1 (de) | 2002-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW428026B (en) | Bifunctional protein, preparation and use | |
WO1999033869A3 (en) | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use | |
NZ516381A (en) | Lung tumor proteins in the therapy and diagnosis of lung cancer | |
WO2001072295A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
MX9603532A (es) | Sistema de suministro de acido nucleico, metodo de sintesis y sus usos. | |
WO2001062794A3 (en) | 18607, a human calcium channel | |
BG100771A (en) | Hematopoeic protein and ways and methods for its preparation | |
WO2000073801A3 (en) | Breast, gastric and prostate cancer associated antigens and uses therefor | |
WO1999040197A3 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf | |
WO1997008318A3 (en) | Compounds and methods for treatment and diagnosis of prostate cancer | |
EP1571216A3 (en) | Phosphodiesterase 8A | |
AU3477295A (en) | Modified proteins | |
WO1997026322A3 (en) | Methods and compositions for inhibiting hexokinase | |
EP1304123A3 (en) | Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections | |
WO2000029551A3 (en) | Cells, culture methods, and their use in autologous transplantation therapy | |
CA2336261A1 (en) | Cyclin e2 genes and proteins | |
IL207012A (en) | 28sgp medicinal product and 28sgp accent cancer treatment vaccine | |
WO2001090152A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
WO1998012327A3 (en) | Compositions and methods comprising bard1 and other brca1 binding proteins | |
EA200000270A1 (ru) | КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
HK1002284A1 (en) | Novel implant and novel vector for the treatment of acquired diseases | |
GB0004576D0 (en) | Proteins | |
EP0839908A3 (en) | A novel human ETS family member, ELF3 | |
IL129139A0 (en) | Vertebrate smoothened proteins | |
WO2002000174A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent |